RxDoctor Payments Data

Taylor Vaughan, MD

Urology · North Charleston, SCNPI 1467770131

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.1% of the total across 495 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations.

$12,321in general payments, 2019–2025

Across 495 payments — averaging $24.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Astellas Pharma US Inc$1K
  • Axonics, Inc.$1K
  • Johnson & Johnson$917
  • Coloplast$840
  • Medtronic$807
  • plus $6K from 46 others

What the payments were for

  • Food & beverage$11,83996%
  • Education$4824%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,321 in reported general payments places this provider in the 85th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$279,056
Medicare patients
500
Services billed
3,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron91$70,277
GemtesaVibegron40$35,189
Mirabegron ErMirabegron16$9,820
Tamsulosin Hcl358$5,250
Desmopressin Acetate22$2,273
Cephalexin86$1,749
Finasteride121$1,685
Testosterone Cypionate41$1,598
Estradiol17$1,156
Potassium Citrate ErPotassium Citrate11$834
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$832
Cefdinir48$646
Ciprofloxacin Hcl87$557
Oxybutynin Chloride ErOxybutynin Chloride15$373
Solifenacin Succinate12$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,193$70,27791 claims
Sumitomo Pharma America, Inc.Gemtesa$526$35,18940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 196 urology providers in South Carolina.

Other urology in North Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →